易瑞生物
(300942)
| 流通市值：25.82亿 | | | 总市值：31.63亿 |
| 流通股本：3.27亿 | | | 总股本：4.01亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 500,350,775.27 | 481,748,962.98 | 648,551,039.12 | 229,095,093.36 |
| 应收票据及应收账款 | 60,479,844.71 | 76,148,249.35 | 69,280,288.69 | 61,260,591.72 |
| 其中：应收票据 | - | - | 257,786 | 22,354 |
| 应收账款 | 60,479,844.71 | 76,148,249.35 | 69,022,502.69 | 61,238,237.72 |
| 应收款项融资 | 397,758 | 50,000 | - | - |
| 预付款项 | 9,757,421.05 | 5,965,094.18 | 13,610,203.47 | 21,769,096.26 |
| 其他应收款合计 | 13,552,857.06 | 10,274,447.54 | 19,048,935.69 | 17,096,759.65 |
| 存货 | 34,971,557.16 | 31,460,650.93 | 63,313,211.1 | 68,324,611.01 |
| 其他流动资产 | 9,827,980.65 | 11,994,837.96 | 8,579,969.24 | 92,869,411.05 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 749,654,790.93 | 737,670,284.61 | 822,383,647.31 | 542,567,633.12 |
| 非流动资产: | | | | |
| 长期股权投资 | 143,019,163.19 | 145,178,660.06 | 191,529,017.11 | 192,887,867.12 |
| 固定资产 | 55,024,820.5 | 57,101,989.09 | 91,855,129.59 | 88,648,406.9 |
| 在建工程 | 393,165,755 | 356,626,085.09 | 273,324,764.55 | 247,957,020.32 |
| 使用权资产 | 8,895,091.47 | 12,796,761.57 | 19,955,636.08 | 23,348,354.49 |
| 无形资产 | 41,049,495.5 | 41,392,739.22 | 41,246,587.42 | 41,659,809.19 |
| 长期待摊费用 | 1,748,238.74 | 1,926,281.79 | 12,332,854.34 | 7,233,465.68 |
| 递延所得税资产 | 3,112,243.91 | 3,056,199.72 | 19,288,913.9 | 29,222,462.83 |
| 其他非流动资产 | 465,277.78 | 590,277.78 | 3,402,108.82 | 9,800,667.46 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 646,480,086.09 | 618,668,994.32 | 652,935,011.81 | 640,758,053.99 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,396,134,877.02 | 1,356,339,278.93 | 1,475,318,659.12 | 1,183,325,687.11 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 78,592,178.99 | 77,352,089.81 | 48,792,150.05 | 58,741,550.96 |
| 应付账款 | 78,592,178.99 | 77,352,089.81 | 48,792,150.05 | 58,741,550.96 |
| 预收款项 | - | - | 1,903.48 | - |
| 合同负债 | 18,069,389.03 | 18,645,867.31 | 33,020,421.66 | 31,518,346.44 |
| 应付职工薪酬 | 13,689,423.78 | 19,135,830.39 | 20,078,859.97 | 18,836,367.24 |
| 应交税费 | 1,485,951.87 | 1,213,639.5 | 1,669,075.38 | 8,408,536.05 |
| 其他应付款合计 | 4,466,333.4 | 4,676,469.01 | 7,998,878.68 | 5,868,573.23 |
| 一年内到期的非流动负债 | 13,606,760.18 | 14,754,180.63 | 19,371,391.95 | 20,190,171.88 |
| 其他流动负债 | 991,367.56 | 1,149,008.69 | 1,802,551.23 | 1,742,210.58 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 130,901,404.81 | 136,927,085.34 | 132,735,232.4 | 145,305,756.38 |
| 非流动负债: | | | | |
| 长期借款 | 147,768,840.48 | 100,329,007.32 | 120,648,882.19 | 102,791,120.59 |
| 应付债券 | 250,337,451.25 | 245,451,700.68 | 239,591,914.67 | - |
| 租赁负债 | 3,619,170.57 | 5,336,306.87 | 11,028,460.15 | 13,932,191.21 |
| 预计负债 | 3,023,500 | 3,023,500 | 2,080,000 | 2,080,000 |
| 递延收益 | 17,046,984.55 | 16,543,447.11 | 20,875,408.36 | 22,053,987.73 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 421,795,946.85 | 370,683,961.98 | 394,224,665.37 | 140,857,299.53 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 552,697,351.66 | 507,611,047.32 | 526,959,897.77 | 286,163,055.91 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 400,865,001 | 400,860,000 | 400,860,000 | 400,860,000 |
| 其他权益工具 | 69,387,082.16 | 69,403,128.86 | 81,650,739.83 | - |
| 资本公积 | 186,642,320.6 | 186,590,042.27 | 186,581,963.3 | 186,581,963.29 |
| 其他综合收益 | 49,651.9 | 115,929.29 | 1,708,278.37 | 2,622,166.44 |
| 盈余公积 | 53,580,647.83 | 53,580,647.83 | 53,580,647.83 | 53,580,647.83 |
| 未分配利润 | 131,333,056.67 | 138,444,134.81 | 224,193,350.21 | 253,719,611.41 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 841,857,760.16 | 848,993,883.06 | 948,574,979.54 | 897,364,388.97 |
| 少数股东权益 | 1,579,765.2 | -265,651.45 | -216,218.19 | -201,757.77 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 843,437,525.36 | 848,728,231.61 | 948,358,761.35 | 897,162,631.2 |
| 负债和股东权益合计 | 1,396,134,877.02 | 1,356,339,278.93 | 1,475,318,659.12 | 1,183,325,687.11 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-27 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |